Barbra J. Mason Ph.D. -
Member, RiverMend Health Scientific Advisory Board for Addiction & Psychiatry. Pearson Family Professor, Committee on the Neurobiology of Addictive Disorders
Co-Director, The Pearson Center for Alcoholism and Addiction Research.
Dr. Mason addresses the RiverMend Health Scientific Advisory Board on the biological processes that occur in the brain of addict and the recovery processes to help counter these processes.
To watch lecture visit : http://vimeo.com/100308628
For more information visit: http://www.rivermendhealth.com/scientific-advisory-board-addiction.html
Best Rate (Guwahati ) Call Girls Guwahati ⟟ 8617370543 ⟟ High Class Call Girl...
Translating the Neurobiology of Addiction Into New Treatments: Medication Assisted Recovery
1. Translating the Neurobiology of
Addiction Into New Treatments:
Medication Assisted Recovery
Barbara J. Mason, Ph.D.
Pearson Family Professor, Committee on the Neurobiology of Addictive Disorders
Co-Director, The Pearson Center for Alcoholism and Addiction Research
SAB Malibu Beach
Sept. 29 & 30, 2013
5. Nucleus Accumbens (Binge-intoxication) — Structure in the front bottom of the brain involved in the
rewarding effects of drugs of abuse that is a key part of the binge/intoxication stage of addiction.
Contains reward neurotransmitters dopamine and opioid peptides that are involved in the
euphoric effects of addiction.
Extended Amygdala (Withdrawal-negative affect) — A set of structures in the front middle of the brain
that include the central nucleus of the amygdala, bed nucleus of the stria terminalis, and part of
the nucleus accumbens. Contains brain “stress” neurotransmitter corticotropin-releasing factor
that produces dysphoria during withdrawal in addiction.
Prefrontal Cortex (“Craving”)— Structure in the front top of the brain involved in executive function
that plays a key role in relapse to addiction. Executive function combines elements of delay in
gratification and inhibition to allow healthful choices and decisions. Contains the major
excitatory neurotransmitter glutamate that reawakens “craving”.
9. Substance abuse treatment has proven efficacy, is cost effective, and
has gained parity with other medical disorders for reimbursement by
3rd
party payors
Identify and pre-clinically validate novel targets
Re-purpose available drugs and shelved investigational drugs for
other indications
Develop vaccines and novel routes of administration
•Use human laboratory studies for proof of concept
•Increase addiction medicine training programs and fellowships to
expand the network of prescribers
10. Substance abuse treatment has proven efficacy, is cost effective, and
has gained parity with other medical disorders for reimbursement by
3rd
party payors
Identify and pre-clinically validate novel targets
Re-purpose available drugs and shelved investigational drugs for
other indications
Develop vaccines and novel routes of administration
•Use human laboratory studies for proof of concept
•Increase addiction medicine training programs and fellowships to
expand the network of prescribers